期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 9, 期 6, 页码 S1-S122出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2015.09.002
关键词
Clinical recommendations; Dyslipidemia; Lifestyle therapies; Children; Elderly; Human immunodeficiency virus; Rheumatoid arthritis; Residual risk; Adherence; Team-based care
资金
- Merck and Co
- Amarin
- Amgen
- AstraZeneca
- Regeneron/Sanofi-Aventis
- AbbVie
- Matinas BioPharma
- Pharmavite
- Sancilio Co.
- DuPont
- ACH Foods
- Shaklee
- Egg Nutrition Center
- National Dairy Council
- National Cattlemen's Beef Association
- Hershey Foods and Almond Board of CA
- Solae/DuPont
- California Strawberry Commission
- California Walnut Commission
- Ag Canada
- Canola Oil Council
- Ocean Spray Cranberries
- Merck Sharpe Dohme
- Novo Nordisk Inc.
- Arena Pharmaceuticals
- Boehringer Ingelheim
- Cargill Inc
- GlaxoSmithKline
- Novo Nordisk
- Orexigen Therapeutics
- Shionogi
- Takeda
- Stratum Nutrition
- California Raisin Board
- Esperion
- Essentialis
- Forest
- Gilead Sciences Inc
- Given
- Hoffman-LaRoche
- Home Access
- Novartis
- Sanofi-Aventis
- Otsuka
- Janssen
- Merck
- Omthera
- Pfizer
- Trygg Pharmaceuticals
- TWI Bio
- Xoma
- Ardea Inc
- High Point Pharmaceuticals LLC
- Micropharma Limited
- Trans Tech Pharma Inc
- TIMI
- Pozen
- Regeneron
- Elcelyx
- Bristol-Myers Squibb
- Catabasis
- Daiichi-Sankyo Inc
- Eisai
- Merck Co
- VIVUS
- Zeomedex
- WPU
- Akcea
- Genzyme
- Pfizer Inc.
- Medtelligence
- Vindico
An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care. (C) 2015 National Lipid Association. Published by Elseiver Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据